OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Wearable Remote Patient Monitoring Devices	262
Reply	136
Reply	118
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	112
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	106
Developing a System for Best Performance for Cardiac Transplantation	104
Reply	95
Reply	94
Editorial Board	91
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	88
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure	87
Opportunities for Change in Home Health Care in Heart Failure	84
Correction	79
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy	78
Clinical Implications of the P.V142I TTR Variant	77
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	76
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	73
Contemporary Trends in Heart Failure Mortality	72
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	70
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	70
Eating to Prevent Both Heart and Planetary Failure	68
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	66
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	64
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	64
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	63

Revisiting ICD Therapy for Primary Prevention	62
Associations Between Urinary Metal Levels and Incident Heart Failure	59
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	58
From Loop Diuretics to Closed-Loop Decongestion	58
Curing Ourselves of Toxic Positivity for Hospital-at-Home	57
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	56
Long-Term Effects of Sotatercept on Right Ventricular Function	55
Predictors of Incident Heart Failure Diagnosis Setting	55
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	51
Full issue PDF	51
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	49
Challenges Addressing Prognosis in Advanced Heart Failure	49
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	47
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	46
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials	46
Genetically Proxied Interleukin-6 Signaling Inhibition and Heart Failure Risk	45
NT-proBNP	45
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	45
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	44
GDF-15 in Cardiovascular Disease	44
High NT-proBNP in Heart Failure	43
Reply	43
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	43
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension	43
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	42
Prognosis for Acute Myocarditis	42
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	42
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	41
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	41
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	41
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	41
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	40
Compensation Models in Heart Failure	40
Full Issue PDF	38
From Dispensing Pills to Building Pillars	38
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	37
Racial and Genetic Differences	36
Thank You for the Privilege	36
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	35
A Woman's Work Is Never Done	35
Heart Failure in Women	34
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	33
Heart Failure With Preserved Ejection Fraction	33
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	33
STRONG-HF	33
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	32
The Path Toward a More Equitable Transplant System	32
Advanced Heart Failure in the Cardiac Intensive Care Unit	32
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	32
CD36 Loss-of-Function and Association With Dilated Cardiomyopathy	32

Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension	32
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction	32
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	31
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	31
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	31
Reply	30
Body Composition and Survival in Patients With Heart Failure	30
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	29
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	29
Management of Heart Failure–Related Cardiogenic Shock	28
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	28
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	28
Therapeutic Options in Ambulatory Advanced Heart Failure	28
Risk Factors and Temporal Trends of Maternal Heart Failure	28
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	28
Upper Body Hypoxemia During ECMELLA	28
Policy Changes for Progress	27
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	27
Smoking Cessation Reduces the Risk of Heart Failure	27
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	26
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	26
Geographic Variation in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	26
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	26
Obesity and Weight Loss Strategies for Patients With Heart Failure	26
Reevaluating Growth Hormone Therapy in HFrEF	26
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	26
Diabetes Therapy With SGLT2i After Heart Transplant	26
Every Journey Needs a Guide	26
Rethinking Lifelong Management of Heart Failure Care in Young Adults	26
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	26
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022	26
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	25
Facts and Fallacies of Body Composition Analysis in Heart Failure	25
Tafamidis in Octogenarians	25
Full issue PDF	25
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	25
REPLY	25
Critical Importance of Genetic Screening in Family Members	25
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	25
Understanding and Investigating Sex-Based Differences in Heart Transplantation	25
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	25
Instructions for Authors	25
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	24
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	24
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	24
Jump Starting the Heart	24
Setting the Diagnosis of Heart Failure	24
Full issue PDF	24
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	23
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	23
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	23
Isolating Noise From Signals in the Air	23
From Better Models to Better Care	23
Heart Replacement Therapy	23
Redefining Pre–Heart Failure With Cardiac Biomarkers	23
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	23
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	23
Expanded Definition of Worsening Heart Failure	23
Illuminating a Hidden Risk	23
Beyond Coronary Atherosclerosis	23
Venting the Venous Circulation	23
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	23
Editorial Board	23
Secondary Mitral Regurgitation Trajectories and Prognosis With Intensification of Guideline-Directed Medical Therapy in Heart Failure	23
Treatment of Obesity in Heart Failure	23
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	22
Severe Myocarditis Increase in Children Associated With Parvovirus B19 Infection	22
To Infinity and Beyond	22
Unreliable HFpEF Diagnosis by H2FPEF in AF	21
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	21
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	21
Moving From Prompts to Praxis With Remote Monitoring	21
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	21
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	20
Full Issue PDF	20
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	20
Global Heart Failure Trends in Young Adults	19
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	19
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	19
Correction	19

Diet and Heart Failure	19
HFpEF Scores	19
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	19
Istaroxime in HFpEF	19
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	19
Physical Activity Trajectories Preceding Incident Heart Failure	19
All That Glitters Is Not Gold	19
Bereavement and Mortality in Heart Failure	19
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	19
The Link Between Heart Failure and Neurodegeneration	19
Reply	19
Articulating the JACC Journals’ Direction in Times of Global Change	18
Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure	18
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	18
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	18
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	18
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure	18
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	18
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	18
REPLY	18
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	18
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	17
Artificial Intelligence to Extract Structured Details From Unstructured Medical Records in a Global Heart Failure Trial	17
Impact of Female Sex on Cardiogenic Shock Outcomes	17
Deactivation of Left Ventricular Assist Devices at the End of Life	17
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	17
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	17
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	17
Thin Evidence, Heavy Need	16
Reply	16
Full issue PDF	16
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	16
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	16
Targeting Inflammation in Heart Failure Prevention	16
Shedding Light on the Darkness of MYH7 Cardiomyopathies	16
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	16
Low Serum Ferritin Might Predict Incident Heart Failure	16
Navigating the Global Burden of Pulmonary Arterial Hypertension	16
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	16
Reducing Pediatric Heart Failure Readmissions	16
Correction	16
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	16
Medication Optimization Clinic	16
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	16
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	15
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	15
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	15
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	15
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	15
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	15
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	15
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	15
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	14
Redefining Boundaries in Heart Failure Care	14
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	14
Exercise-Induced Versus Resting Left Atrial Hypertension	14
Correction	14
Reply	14
Aging in Heart Failure	14
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	14
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	14
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	14
Iron Deficiency Definition and Management in Patients With Heart Failure	14
Contemporary American and European Guidelines for Heart Failure Management	14
The Enigma of Natriuretic Peptides	14
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	14
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	13
The HeartMate 3 Risk Score	13
BMI in HFpEF	13
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	13
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	13
Better 3 Hours Too Soon Than 1 Minute Late	13
Reflections on Early Rehabilitation in Acute Heart Failure	13
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	13
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	13
Coronary Artery Disease Is Still a Major Cause of Heart Failure	13
Information for Authors	13
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	13
Pregnancy as a Sentinel Event	13
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	12
Echo-Based, Artificial Intelligence Algorithm Identifies Future Heart Failure Cases	12
Promoting Representation in Heart Failure Clinical Trials	12
Full issue PDF	12
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	12
When the Data Changes, So Should We	12
Officers Page	12
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	12
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	12
REPLY	12
From Fuel to Flow	12
Can Sensor Implantation Alone Reduce Heart Failure Hospitalizations Without Need for Structured Management Based on its Data?	12
Low Education Levels Linked to Increased Mortality Following Acute Heart Failure Hospitalization in Brazil	12
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	12
Persistent Disparities in Heart Failure	12
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	12